1405 related articles for article (PubMed ID: 32475638)
21. Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis.
Yoshimine Y; Uto H; Kumagai K; Mawatari S; Arima S; Ibusuki R; Mera K; Nosaki T; Kanmura S; Numata M; Tamai T; Moriuchi A; Tsubouchi H; Ido A
Oncol Rep; 2015 Apr; 33(4):1657-66. PubMed ID: 25607821
[TBL] [Abstract][Full Text] [Related]
22. Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis.
Son YJ; Jung DS; Shin JM; Kim M; Yoo G; Nho CW
BMC Complement Med Ther; 2021 Jan; 21(1):44. PubMed ID: 33494735
[TBL] [Abstract][Full Text] [Related]
23. Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver.
Igreja Sá IC; Tripska K; Hroch M; Hyspler R; Ticha A; Lastuvkova H; Schreiberova J; Dolezelova E; Eissazadeh S; Vitverova B; Najmanova I; Vasinova M; Pericacho M; Micuda S; Nachtigal P
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261044
[TBL] [Abstract][Full Text] [Related]
24. Strain- and time-dependent alterations in hepatic iron metabolism in a murine model of nonalcoholic steatohepatitis.
Bloomer SA; Olivier AK; Bergmann OM; Mathahs MM; Broadhurst KA; Hicsasmaz H; Brown KE
Cell Biochem Funct; 2016 Dec; 34(8):628-639. PubMed ID: 27935134
[TBL] [Abstract][Full Text] [Related]
25. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
[TBL] [Abstract][Full Text] [Related]
26. Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet.
Miguel FM; Picada JN; da Silva JB; Schemitt EG; Colares JR; Hartmann RM; Marroni CA; Marroni NP
Inflammation; 2022 Oct; 45(5):1968-1984. PubMed ID: 35419738
[TBL] [Abstract][Full Text] [Related]
27. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
[TBL] [Abstract][Full Text] [Related]
28. The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
Bae CR; Zhang H; Kwon YG
PLoS One; 2020; 15(12):e0243497. PubMed ID: 33275637
[TBL] [Abstract][Full Text] [Related]
29. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
30. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
31. The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse.
Takano K; Kaneda M; Aoki Y; Fujita N; Chiba S; Michihara S; Han LK; Takahashi R
J Nat Med; 2024 Jun; 78(3):514-524. PubMed ID: 38498120
[TBL] [Abstract][Full Text] [Related]
32. Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis.
Marin V; Gazzin S; Gambaro SE; Dal Ben M; Calligaris S; Anese M; Raseni A; Avellini C; Giraudi PJ; Tiribelli C; Rosso N
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28895929
[TBL] [Abstract][Full Text] [Related]
33. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
34. Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice.
Jiang JX; Tomilov A; Montgomery C; Hui CK; Török NJ; Cortopassi G
J Biochem Mol Toxicol; 2021 Oct; 35(10):e22876. PubMed ID: 34369032
[TBL] [Abstract][Full Text] [Related]
35. Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease.
Toita R; Kang JH
Toxicol Lett; 2020 Oct; 332():1-6. PubMed ID: 32579995
[TBL] [Abstract][Full Text] [Related]
36. Cangju Qinggan Jiangzhi Decoction Reduces the Development of NonAlcoholic Steatohepatitis and Activation of Kupffer Cells.
Cheng Y; Chen T; Ping J; Chen J
Cell Physiol Biochem; 2018; 48(3):971-982. PubMed ID: 30036865
[TBL] [Abstract][Full Text] [Related]
37. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
38. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
[TBL] [Abstract][Full Text] [Related]
39. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852
[TBL] [Abstract][Full Text] [Related]
40. Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis.
Suga T; Yamaguchi H; Ogura J; Shoji S; Maekawa M; Mano N
Toxicol Appl Pharmacol; 2019 Sep; 379():114664. PubMed ID: 31306673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
